Dibenzothiazepine derivatives and use thereof

Details for Australian Patent Application No. 2009260905 (hide)

Owner AstraZeneca AB

Inventors Pierson Jr., M. Edward; Wesolowski, Steven; Muir, James Campbell; Edwards, Phil; Shenvi, Ashokkumar Bhikkappa; Damewood, James R.; Widzowski, Dan; Wood, Michael; Hulsizer, James; Brown, Dean

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2009260905

PCT Pub. Number WO2009/154563

Priority 61/074,417 20.06.08 US

Filing date 18 June 2009

Wipo publication date 23 December 2009

Acceptance publication date 23 August 2012

International Classifications

C07D 281/16 Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms

A61K 31/554 - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61P 25/18 Drugs for disorders of the nervous system

A61P 25/24 Drugs for disorders of the nervous system

Event Publications

20 January 2011 PCT application entered the National Phase

  PCT publication WO2009/154563 Priority application(s): WO2009/154563

23 August 2012 Application Accepted

  Published as AU-B-2009260905

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009260907-Combination therapies against cancer

2009260904-Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity